In spite of the efficacy of other antiplatelets in this indication 鈥 ticlopidine (500 mg), clopidogrel (75 mg) and dipyridamole (400 mg) 鈥 aspirin remains the most cost-effective, doses between 100 and 300 mg being the most widely used. Cardiac diseases with a high embolic risk ...
In spite of the efficacy of other antiplatelets in this indication — ticlopidine (500 mg), clopidogrel (75 mg) and dipyridamole (400 mg) — aspirin remains the most cost-effective, doses between 100 and 300 mg being the most widely used. Cardiac diseases with a high embolic risk require...